Recently, Shanghai Sakya Biotechnology Co., Ltd. (hereinafter referred to as “Sakya Bio”) announced the completion of tens of millions of A-round financing. This round of financing was led by Zhang Keherun, a professional biomedical fund under Zhangjiang Science and Technology Investment, followed by investors such as Qingdao Zhenze Fund.
Saga Bio said that after this round of financing, the company will accelerate the productization and commercialization of its own original new protein chip platform, and through cooperation with hospitals, scientific research institutions, antibody raw material companies, clinical and scientific research experts, the solid-phase protein chip will be fully utilized. The advantages of the platform’s high-throughput, multi-index joint inspection, and high cost performance promote the application of this technology platform in many fields such as in vitro diagnostics and life sciences.
Saga Biotech was established in Zhangjiang Medicine Valley Incubator in April 2017. The company’s core technical team has been focusing on the R&D and industrialization of technologies such as solid-phase protein chips, new biological materials and advanced instrument manufacturing for many years. Based on independent innovation, Saga Biocombines technologies such as special-function silica gel membrane, near-infrared fluorescent labeling and laser confocal scanning to form a brand-new solid-phase protein chip detection platform. With technological innovation, it has greatly improved in detection sensitivity, accuracy, and ease of use.
Saga Bio is one of the first batch of enterprises in Zhangjiang to carry out the registrant pilot program. More than 70% of the company’s personnel are R&D personnel. All instrument products and reagent products are produced by entrusted production. The company’s funds are concentrated in R&D and clinical cooperation.
The company has a global layout and simultaneously carries out product registration declarations in China, the United States and Europe. At present, one instrument product has completed the US FDA registration certification; one instrument product and three reagent products have obtained EU CE certification; domestic registration declaration is also being implemented steadily, and one instrument product and two reagent products are in the registration review stage , is expected to be approved for listing within the year.
Saga Biotech is forming a product line of “general IVD reagents, clinical special testing reagents and scientific research testing reagents”.
media reports
Arterial Network Arterial Network Entrepreneurship State
related events
- “Sakya Bio” completed tens of millions of A-round financing, led by Zhang Keherun2023-01-17
- Baikang Biotech completed the A-round financing of nearly 100 million yuan, and Fangsheng Fund led the investment2023-01-12
- Ruixun Biotech received tens of millions of C1 round financing2022-11-17
- Ketaiya Biotech completed the A+ round of financing exceeding RMB 100 million2022-11-07
- Jiayu Biology completed the B round of financing of 10 million US dollars2022-09-15
This article is transferred from: https://readhub.cn/topic/8mEqLmAFTC4
This site is only for collection, and the copyright belongs to the original author.